ALKEM LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,569 INR | -1.71% |
|
-3.46% | -12.01% |
| Mar. 28 | Alkem Laboratories Forms Subsidiary for Medical Devices Business | MT |
| Mar. 28 | Alkem Laboratories Limited Announces Incorporation of Subsidiary Alkem Medtech Private Limited | CI |
| Sales 2024 * | 129B 1.55B | Sales 2025 * | 142B 1.71B | Capitalization | 556B 6.66B |
|---|---|---|---|---|---|
| Net income 2024 * | 18.89B 226M | Net income 2025 * | 21.82B 261M | EV / Sales 2024 * | 4.15 x |
| Net cash position 2024 * | 20.12B 241M | Net cash position 2025 * | 27.86B 334M | EV / Sales 2025 * | 3.71 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
25.6
x | Employees | 16,871 |
| Yield 2024 * |
0.93% | Yield 2025 * |
1.05% | Free-Float | 36.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkem Laboratories Limited
More recommendations
More press releases
| 1 day | -1.71% | ||
| 1 week | -3.46% | ||
| Current month | -7.51% | ||
| 1 month | -6.13% | ||
| 3 months | -7.95% | ||
| 6 months | +26.36% | ||
| Current year | -12.01% |
1 week
4 569.15
4 771.00
1 month
4 569.155 094.00
Current year
4 569.155 519.10
1 year
3 211.055 519.10
3 years
2 710.655 519.10
5 years
1 660.355 519.10
10 years
1 175.005 519.10
| Managers | Title | Age | Since |
|---|---|---|---|
Vikas Gupta
CEO | Chief Executive Officer | - | 23-09-21 |
Nitin Agrawal
DFI | Director of Finance/CFO | - | Jan. 31 |
Manish Narang
CMP | Compliance Officer | 54 | 06-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | - | |
| Director/Board Member | 77 | 15-03-15 | |
| Chief Executive Officer | 84 | 73-08-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 4,569 | -1.71% | 951 |
| 24-04-18 | 4,649 | -1.81% | 3,112 |
| 24-04-16 | 4,734 | +0.54% | 1,661 |
| 24-04-15 | 4,709 | -0.50% | 1,682 |
| 24-04-12 | 4,733 | -1.93% | 6,294 |
Delayed Quote Bombay S.E., April 19, 2024 at 01:38 am EDT
More quotes
Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Companyâs product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
4,651
INR
Average target price
5,184
INR
Spread / Average Target
+11.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- ALKEM Stock
- ALKEM Stock
